Release Date:  March 23, 1999

PA NUMBER:  PAR-99-077


National Cancer Institute

Letter of Intent Receipt Date:  September 7, 1999, May 1, 2000, May 1, 2001
Application Receipt Date:  October 1, 1999; June 1, 2000; June 1, 2001

This Program Announcement (PA) replaces RFA CA-97-008, Clinical Oncology Research
Career Development Program, which was published in the NIH Guide, Vol. 26, No.
3, January 31, 1997.


The purpose of the National Cancer Institute (NCI) Clinical Oncology Career
Development Program is to increase the number of medical doctors (M.D.þs, D.O.þs)
and doctorally degreed Oncology registered nurses who are motivated and properly
prepared to: (1) communicate and coordinate clinical research activities with
basic/behavioral research scientists in order to expedite the translation of
basic/ behavioral research information into patient-oriented research; (2)
perform independent clinical research that develops and tests rational scientific
hypotheses based on fundamental and clinical research findings for improving the
medical care of cancer patients; and (3) design and test innovative clinical
protocols and manage all phases of clinical trial research.  To achieve this
purpose, awards are made to institutions for up to 5 years for the development
and implementation of training programs providing clinicians with all of the
information and training needed to design, implement and manage all phases of
cancer clinical trials research.  Clinicians would be appointed to the training
program, and would likely have more than one mentor as they will be exposed to
the basic sciences and to the many disciplines critical to the clinical sciences. 
Clinicians interested in an individual mentored research experience in basic
research, which can include a translational research component, should refer to
PA-95-053 "Mentored Clinical Scientist Development Award (K08)," published in the
NIH Guide, Vol. 24, No. 15 April 28, 1995.


The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led national
activity for setting priority areas.  This PA, Clinical Oncology Research Career
Development Program, is related to the priority area of cancer.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0 or Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington, DC
20402-9325, Telephone (202) 512-1800, or at


Institution:  Applications may be submitted by domestic, for-profit and
non-profit organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and eligible
agencies of the Federal government.  Racial/ethnic minority individuals, women,
and persons with disabilities are encouraged to apply as principal investigators. 
Applicant organizations should have well-established research programs with
adequate peer-reviewed grant support and highly qualified faculty in clinical,
behavioral and basic science departments.

Principal Investigator and Clinician Candidates: The principal investigator and
all clinician candidates must currently be physicians holding the M.D. or D.O.
degrees, or be doctorally prepared oncology registered nurses; and must have
completed their clinical training.  Clinician candidates must be able to spend
a minimum of 75 percent effort conducting research and research career
development including taking courses during the period of the award.  The
clinician candidates must be U.S. citizens, nationals or lawfully admitted
permanent residents of the U.S.  Individuals admitted for permanent residence
must be able to produce documentation of their immigration status such as an
Alien Registration Receipt Card (I-151 or I-551) or some other verification of
legal admission as a permanent resident.  Non-citizen nationals, although not
U.S. citizens, owe permanent allegiance to the U.S.  They are usually born in
lands that are not states but are under U.S. sovereignty, jurisdiction, or
administration.  Individuals on temporary or student visas are not eligible for
this award.

Ineligible individuals include current or former principal investigators on any
NIH research grants or non-PHS peer reviewed grants that are over $70,000 direct
costs per year, on any NIH mentored career development award that has supported
a career development experience in clinical research ; or on any non-PHS career
development award that essentially duplicates the provisions of the NIH mentored
career development awards or the K12 program.


Support of this program will be through the National Institutes of Health (NIH)
Mentored Clinical Scientist Development Program (K12) mechanism.  Applicants will
be responsible for the planning, direction, and execution of the proposed
project.  Awards will administered under NIH grants policy as stated in the
National Institutes of Health Grants Policy Statement, NIH Publication No. 99-8
October 1998.  The total project period for an application submitted in response
to this PA may not exceed five years. Awards are renewable.


A.  Background:  In 1991 the National Cancer Institute (NCI) recognized the need
for establishing formal training programs that would prepare the next generation
of clinical scientists to participate more effectively in translational clinical
research, which the NCI simply defines as the movement of discoveries in the
laboratory into patient research settings, and observations in patient care
settings into the research laboratory.  The NCI abandoned its previous strategy
of expecting M.D./Ph.D.s to do this alone and embarked on a pilot program
initiative that would prepare clinical oncologists to be effective scientific
partners in the translational research process.  These well-trained clinical
oncologist scientists would be expected to communicate, interact and collaborate
with basic/behavioral scientists in the design and implementation of clinical
trials that were hypothesis driven and based on an understanding of biological
mechanisms.  This pilot program initiative, announced through RFA CA-91-32, was
founded on the following principles: (1) unlike career awards to individuals,
these would be awards to institutions and the institution would appoint
individuals to a formal training program; (2) rather than having a single mentor,
the individuals on the program would likely have more than one mentor as they are
exposed to the basic sciences and to the many disciplines critical to the
clinical sciences; (3) the program would provide individuals with all of the
information and training needed to design, implement and manage all phases of
clinical trials research.

The initial pilot program initiative was highly successful.  The RFA announcement
generated 31 applications, 17 (55%) of which were funded, ultimately providing
support for the training of 62 Clinical Oncologists.  The reissuance of the RFA
(CA-97-008) in 1997 generated 28 applications of which almost one-half (13/28 or
46%) were funded, providing support for the training of 50 Clinical Oncologists. 
Significantly, 13 (46%) of the funded applications submitted in response to the
reissued RFA were competing renewals of programs initiated in response to the
first announcement of the initiative; the success rate of these applications was
61% (8/13).

Based upon these successes, the NCI through its Cancer Training Branch is
announcing the Clinical Oncology Research Career Development Program as an
ongoing Program Announcement (PA) with a once-a-year submission date.
Additionally, due to the critical complementary role of oncology nursing research
in the cancer clinical research team in areas such as informatics, patient
education, decision making, quality of life, symptom management, and
survivorship, the PA extends eligibility to include doctorally prepared oncology
registered nurses. It is anticipated that such a "multidisciplinary" approach
during these formative years of clinical research training will promote the team
approach necessary for conducting clinical oncology research and for optimum
cancer patient care. The levels of salary and research support offered in the
previous RFAþs have been increased in this PA to levels consistent with the
support offered clinicians in the NCI administration of the NIH Mentored Research
Scientist Career Development Award (K08) and the Mentored Patient-Oriented
Research Career Development Award (K23).

B.  Program:  The award provides support to institutions for five consecutive 12-
month periods.  Appointments of clinical candidates to the program are provided
in 12-month increments.  These appointments may be as long as seven years. The
program provides research career development opportunities in more than one
clinical oncology research discipline (e.g., medical oncology, surgical oncology,
radiation oncology, oncology nursing, etc.). Both the didactic and the research
phases of the award are expected to develop the necessary knowledge and research
skills in scientific areas relevant to the career goals of the candidate in
clinical research.  Candidates lacking skills in data management, statistics,
epidemiology, study design, clinical trial design, hypothesis development, drug
development, etc. will be provided the opportunity to participate in courses
designed to overcome these deficiencies.

C. Environment:  The institution must have a well-established research and
clinical career development program, and faculty qualified in clinical research
with an emphasis on patient-oriented research to serve as faculty for the
program.  The research environment should be one in which there are active
basic/behavioral/clinical research collaborations that exemplify a dynamic
two-way exchange of information and ideas between laboratory and clinical
scientists.  The research environment should also promote rapid translation of
basic/behavioral/oncology research into clinical testing as well as stimulate new
ideas and laboratory experiments, based on clinical observations and testing
results.  Finally, the institution must demonstrate a commitment to the
development of trainees as productive, independent investigators.

D.  Allowable costs:

1.  Salary:  Clinical research candidates can be provided salary support of up
to $75,000 each year, plus fringe benefits commensurate with the applicant
institution's salary structure for persons of equivalent qualifications,
experience, and rank.  The institution may supplement the NCI contribution;
however, supplementation may not be from Federal funds unless specifically
authorized by the Federal program from which such funds are derived.  In no case,
may PHS funds be used for salary supplementation.  Institutional supplementation
of salary may not require extra duties or responsibilities that would interfere
with the purpose of this award.  Under expanded authorities, however,
institutions may rebudget funds within the total costs awarded to cover salaries
consistent with the institution salary scale.  The total salary requested must
be based on a full-time, 12 month staff appointment.

2.  Other Expenses: Up to $30,000 per candidate can be provided annually to
partially support supplies, equipment, travel, tuition and other costs which are
essential for the individual's clinical research development program.

3.  Ancillary Personnel Support: Salary for mentors, secretarial and
administrative assistance, etc. is not allowed.

4.  The total cost of the award may not exceed $499,000 in direct costs per

5.  Facilities and Administrative Costs: These costs, which were formerly called
indirect costs, will be reimbursed at 8 percent of modified total direct costs.

6.  Other Income: Fees resulting from clinical practice, professional
consultation, or other comparable activities required by the research and
research-related activities of this award may not be retained by the career award
recipient.  Such fees must be assigned to the grantee institution for disposition
by any of the following methods:

The funds may be expended by the grantee institution in accordance with the NIH
policy on supplementation of career award salaries and to provide fringe benefits
in proportion to such supplementation.  Such salary supplementation and fringe
benefit payments must be within the established policies of the grantee

The funds may be used for health-related research purposes.

The funds may be paid to miscellaneous receipts of the U.S. Treasury.  Checks
should be made payable to the Department of Health and Human Services, NIH and
forwarded to the Director, Division of Financial Management, NIH, Bethesda,
Maryland 20892.  Checks must identify the relevant award account and reason for
the payment.

Awardees may retain royalties and fees for activities such as scholarly writing,
service on advisory groups, or honoraria from other institutions for lectures or
seminars, provided these activities remain incidental and provided that the
retention of such pay is consistent with the policies and practices of the
grantee institution.

Usually, funds budgeted in an NIH supported research or research training grant
for the salaries or fringe benefits of individuals, but freed as a result of a
career award, may not be rebudgeted.  The NCI will give consideration to approval
for the use of released funds only under unusual circumstances.  Any proposed
retention of funds released as a result of a career award must receive prior
written approval of NCI staff.

E.  Special Leave:  Leave to another institution of a trainee, including a
foreign laboratory, may be permitted if directly related to the purpose of the
award.  Only local, institutional approval is required if such leave does not
exceed 3 months.  For longer periods, prior written approval of NCI staff is
required.  To obtain prior approval, the trainee must submit a letter to NCI
Program staff describing the plan, countersigned by his or her department head
and the appropriate institutional official.  A copy of a letter or other evidence
from the institution where the leave is to be taken must be submitted to assure
that satisfactory arrangements have been made.  Support from the award will
continue during such leave.

Leave without award support may not exceed 12 months.  Such leave requires the
prior written approval of the NCI and will be granted only in unusual situations. 
Support from other sources is permissible during the period of leave.  Parental
leave will be granted consistent with the policies of the NCI and the grantee

F.  Termination: When a grantee institution plans to terminate an award, the NCI
must be notified in writing at the earliest possible time so that appropriate
instructions can be given for termination.

G.  Change of Institution:  The Clinical Oncology Career Development Program
(K12) cannot be transferred from one institution to another.

H.  Change of Program Director:  If the program director moves to another
institution or resigns from the position, support of the award may be continued
with NCI prior approval provided:

o  The current program director or the awardee institution has submitted a
written request for change of program director, countersigned by the appropriate
institutional business official, to the NCI Program Director describing the
reasons for the change.  The biosketch of the proposed new program director,
including a complete listing of active research grant support, is provided.  The
information in the request establishes that the specific aims of the original
peer reviewed research program to be conducted under the direction of the new
program director will remain unchanged, and that the new program director has the
appropriate research and administrative expertise to lead the program;

o  The request is submitted far enough in advance of the requested effective date
to allow the necessary time for review.

I.  Changes of Program:  Awards are made to a specific institution for a specific
program under the guidance of a particular program director.  Changes in any of
these parameters requires prior approval by NCI Program staff.

A scientific rationale must be provided for any proposed changes in the aims of
the original peer reviewed program.  The new program will be evaluated by NCI
staff to ensure that the program remains within the scope of the original peer
reviewed research program.  If the new program does not satisfy this requirement,
the award could be terminated.

The Director of the NIH may discontinue an award upon determination that the
purpose or terms of the award are not being fulfilled.  In the event an award is
terminated, the Director of the NIH shall notify the grantee institution and
program director in writing of this determination, the reasons therefore, the
effective date, and the right to appeal the decision.

J.  Progress Reports:  An Annual Progress Report for the grant is required.  This
report should provide a summary of the evaluation of the Advisory Committee and
include a description of the research and career progress of each candidate,
describing how laboratory and clinical research and practice are being
integrated.  These Annual Reports will be closely monitored by NCI staff to
ensure that the grant is achieving the goals of this Clinical Oncology Research
Career Development Program.

A final progress report, invention statement, and Financial Status Report are
required upon either termination of an award or relinquishment of an award in a
change of institution situation.

K.  Evaluation:  In carrying out its stewardship of human resource related
programs, the NCI may request information essential to an assessment of the
effectiveness of this program.  Accordingly, recipients are hereby notified, that
they may be contacted after the completion of this award for periodic updates on
various aspects of their employment history, publications, support from research
grants or contracts, honors and awards, professional activities, and other
information helpful in evaluating the impact of the program.


1.  The Program Director must assemble an Advisory Committee to provide an
oversight function and annual evaluation of the clinical research development
program as a whole.  Clinical, basic and behavioral science departments, and
oncology nursing departments participating in this program should be represented
on the committee by clinical investigators from the various oncology disciplines
such as medical oncology, surgical oncology, radiation oncology, oncology nursing
and other oncology specialties as well as by basic and behavioral research
investigators.  The committee's responsibilities might include: selecting
physician and oncology nurse candidates, assigning preceptors, approving each
candidate's clinical research development plan, evaluating each candidate's
progress, and monitoring the overall effectiveness of the program.  A detailed
description should be provided of the committee's composition, function, and
frequency of meetings. A detailed report of the actions of the committee meetings
must be provided in the annual progress report of the grant.  Plans for an annual
evaluation of the program by the Advisory Committee should be described.

2.  The program must involve staff and clinical candidates representing at least
two clinical oncology disciplines such as medical, surgical, radiation,
pediatric, gynecologic oncology and oncology nursing.

3.  The program should provide clinician candidates with the patient-oriented
research skills that deal directly with aspects of cancer detection, diagnosis,
prognosis, or treatment of cancer patients; and should provide the skills
necessary for translating basic/ behavioral cancer research results into clinical
experiments, procedures, and trials directly involving cancer patients in a
clinical environment.  It will not be sufficient within the scope of this
initiative to use human cells and other clinical materials in an isolated basic
laboratory setting as the total research development program.  Basic
laboratory/behavioral research experience is essential, but it must be properly
integrated with patient-oriented clinical research, thereby affording the
candidate actual experience in the application of their own basic research to
clinical research.

4.  The program should have the flexibility to accommodate clinical candidates
with different levels of research competence.

5.  The program should include a didactic component (e.g. formal courses, lecture
series, seminars, and journal clubs).  In those institutions with a Clinical
Research Curriculum (K30) Award, the didactic component should link with and
incorporate the new didactic programs developed though the K30 award.

6.  Appointments of clinical candidates to the program should be for a minimum
of two years.

7.  A minimum of 75 percent effort must be devoted to the basic/clinical research
program.  The remaining 25 percent can be divided among other clinical and
teaching activities only if they are consonant with the program goals, i.e. the
candidate's development into an independent clinical investigator.

8.  The institution must have a well-established research and clinical career
development program, and faculty qualified in clinical research with an emphasis
on patient-oriented research to serve as faculty for the program.  The research
environment should be one in which there are active basic/behavioral/clinical
research collaborations that exemplify a dynamic two-way exchange of information
and ideas between laboratory and clinical scientists.  The research environment
should also promote rapid translation of basic/behavioral/oncology research into
clinical testing as well as stimulate new ideas and laboratory experiments, based
on clinical observations and testing results.

9. The institution must demonstrate a commitment to the development of trainees
as productive, independent investigators.

10. Where there already exists an active institutional (T32) National Research
Service Award (NRSA) supporting a surgical or other clinical oncology research
training program, the applicant must address the relationship between the
existing T32 and proposed K12 programs.  If there is significant overlap in the
programs, the T32 award can be merged into the K12 program or modified to remove
areas of substantial overlap.


It is the policy of the NIH that women and members of minority groups and their
subpopulations must be included in all NIH supported biomedical and behavioral
research projects involving human subjects, unless a clear and compelling
rationale and justification are provided that inclusion is inappropriate with
respect to the health of the subjects or the purpose of the research.  This
policy results from the NIH Revitalization Act of 1993 (Section 492B of Public
Law 103-43).

All investigators proposing research involving human subjects should read the
"NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical
Research" which have been published in the Federal register of March 28, 1994 (FR
59 14508-14513), and in the NIH Guide for Grants and Contracts, Vol. 23, No. 11,
March 18, 1994. It is also available electronically at URL address:

Investigators may also a obtain copy of the policy from the program staff or
contact person listed under INQUIRIES. Program staff may also provide additional
relevant information concerning the policy.


It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by NIH,
unless there are clear and compelling scientific and ethical reasons not to
include them. This policy applies to all initial (Type 1) applications submitted
for receipt dates after October 1, 1998.

All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines on the Inclusion of Children as Participants in
Research Involving Human Subjects" that was published in the NIH GUIDE FOR GRANTS
AND CONTRACTS, March 6, 1998 and is available at the following URL address:


Prospective applicants are asked to submit, by the dates listed at the beginning
of this PA, a letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Principal Investigator,
the identities of other key personnel and participating institutions, and the
number and title of the PA in response to which the application may be submitted. 
Although a letter of intent is not required, is not binding, and does not enter
into the review of a subsequent application, the information that it contains
allows NCI staff to estimate the potential review workload and avoid conflict of
interest in the review.

The letter of intent is to be sent to the program staff listed under INQUIRIES.


Applications are to be submitted on the grant application form PHS 398 (rev.
4/98) using the instructions in Section V of the application kit, and will be
accepted on the receipt dates indicated at the beginning of this PA. 
Applications should follow Just-In-Time (JIT) procedures.

Application kits are available at most institutional offices of sponsored
research and from the Division of Extramural Outreach and Information Resources,
National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD
20892-7910, telephone 301/710-0267, Email:  Applications kits
are also available at:

The title and number of the program announcement must be typed in Section 2 on
the face page of the application and the YES box must be marked.  Refer to the
following URL for guidelines on modifications specific to this PA that must be
incorporated into the organization and content of this application:

The completed original application and three legible copies must be sent to or
delivered to:

BETHESDA, MD  20892-7710
BETHESDA, MD  20817 (For express/courier service)

At the time of submission, two additional copies must also be sent to:

Ms. Toby Friedberg
Referral Officer
Division of Extramural Activities
National Cancer Institute
6130 Executive Boulevard, Room 636
Bethesda, MD  20892-7405
Rockville, MD  20852 (express/courier service)

Applications will be accepted on October 1, 1999; June 1, 2000; and June 1, 2001. 
If an application is received after the deadline, it will be returned to the
applicant without review.  If the application submitted in response to this PA
is substantially similar to a grant application already submitted to the NIH for
review but has not yet been reviewed, the applicant will be asked to withdraw
either the pending application or the new one.  Simultaneous submission of
identical applications will not be allowed, nor will essentially identical
applications be reviewed by different review committees.  An application,
therefore, cannot be submitted in response to this PA which is essentially
identical to one that has already been reviewed.  This does not preclude the
submission of substantial revisions of applications already reviewed, but such
applications must include an introduction addressing the previous critique.

The information summarized below must be provided in this application in the
suggested NCI-format found at

o  Career Development Plan for the clinical candidates;

o  Program Direction and Management;

o  Composition and role of the Advisory Committee;

o  Research funded activities, resources, facilities and mentors affiliated with
the program;

o  Recruitment Strategies;

o  Protection of human subjects and vertebrate animals;

o  Plans for training in ethical conduct of research;

o  Budget.


Upon receipt, applications will be reviewed for completeness by the Center for
Scientific Review (CSR) and by the NCI for responsiveness.  Applications that are
complete and responsive to the PA will be evaluated for scientific and technical
merit by an appropriate peer review group convened by the NCI in accordance with
the standard NIH peer review procedures.  As part of the initial merit review,
all applications will receive a written critique and undergo a process in which
only those applications deemed to have the highest scientific merit, generally
the top half of applications under review, will be discussed, assigned a priority
score, and receive a second level review by the National Cancer Advisory Board.

Review Criteria

The review criteria that will be applied to the application are briefly described
here.  The applicant should refer for additional details to the following URL:

o  Adequacy and appropriateness of the plan for Career Development, and the focus
of the plan on development of the translational and patient-oriented skills of
the appointees to the Program;

o  Adequacy of the plan for Program Direction and Management;

o  Adequacy of the Advisory Committee to perform itþs required oversight,
monitoring and evaluative functions;

o  (For institutions with an active K30 grant), appropriateness and adequacy of
the linkage   between the didactic component of the K12 program and the K30-
derived curriculum;

o  Appropriateness and adequacy of the research funded activities, resources,
facilities and mentors affiliated with the program;

o  Adequacy of Proposed Strategies for Recruitment of Clinicians into the

o  Adequacy of the proposed means for protecting human subjects and vertebrate
animals against hazardous or unethical research procedures and for protecting the
privacy of human subjects;

o  Adequacy of plans for training in the ethical conduct of research;

o  Budget:  The review group will critically examine the proposed budget and
recommend an  appropriate budget for each approved application within the
guidelines stated above.

The initial review group will also examine: the appropriateness of the proposed
project duration; the adequacy of plans to include both genders and minorities
in their subgroups as appropriate for the scientific goals of the research and
plans for the recruitment and retention of subjects; the adequacy of plans for
including children as appropriate for the scientific goals of the research, or
justification for exclusion; the provisions for the protection of human and
animal subjects; and the safety of the research environment.


Applications will compete for available funds with all other scored applications
submitted in response to this PA.  The following will be considered in making
decisions: quality of the proposed project as determined by peer review,
availability of funds and program priority.  The NCI will notify the applicant
of the National Cancer Advisory Board's (NCAB) action.


The procedures for submission of a new or a competing renewal application are not
applicable to applications for a non-competing renewal of an award.   Applicants
should refer for directions on preparing a non-competing renewal application for
this award to the SUPPLEMENTAL GUIDELINES in the NCI-specific guidelines for this
program at the following URL:


Inquiries are encouraged. The opportunity to clarify any issues or questions from
potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Dr. Lester S. Gorelic
Training and Resources Program
National Cancer Institute
6130 Executive Boulevard, MSC 7390
Bethesda, MD 20892-7390
Telephone: (301) 496-8580
FAX: (301) 402-4472

Dr. Andrew Vargosko
Training and Resources Program
National Cancer Institute
6130 Executive Boulevard, MSC 7390
Bethesda, MD 20892-7390
Telephone: (301) 496-8580
FAX: (301) 402-4472

Direct inquiries regarding fiscal matters to:

Ms. Catherine Blount
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
Bethesda, MD 20892
Telephone: (301) 496-7800, ext. 262
FAX: (301) 496-8601

Direct inquiries regarding review issues to:

Ms. Toby Friedberg
Division of Extramural Activities
National Cancer Institute
6130 Executive Boulevard, Room 636, MSC 7399
Rockville, MD  20850 (express/courier service)
Bethesda, MD  20892-7399
Telephone: (301) 496-3428
Fax: (301) 402-0275


This program is described in the Catalog of Federal Domestic Assistance No.
93.398 Cancer Research Manpower.  Awards are made under authorization of sections
301 and 405 of the Public Health Service Act, as amended (42 USC 241 and 284) and
administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45
CFR Part 74 and part 92.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency review.

The PHS strongly encourages all grant and contract recipients to provide a smoke-
free workplace and promote the non-use of all tobacco products.  In addition,
Public Law 103-227, the Pro- Children Act of 1994, prohibits smoking in certain
facilities ( or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care or early childhood development
services are provided to children.  This is consistent with the PHS mission to
protect and advance the physical and mental health of the American people.

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.